Vivos Therapeutics Receives Nasdaq Delisting Notice for Equity Deficiency

summarizeSummary

Vivos Therapeutics received a formal notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, initiating a process that could lead to delisting if a compliance plan is not accepted or met.

check_boxKey Events

• Nasdaq Non-Compliance Notice Received

  On April 17, 2026, Vivos Therapeutics received a letter from Nasdaq indicating non-compliance with the Minimum Stockholders' Equity Requirement (Rule 5550(b)(1)).

• Equity Deficiency Identified

  As of December 31, 2025, the company reported negative stockholders' equity of approximately $1.55 million, falling below the required $2.5 million. This follows the 'going concern' warning in the recent 10-K.

• Compliance Plan Deadline Set

  The company has 45 calendar days, until June 1, 2026, to submit a plan to regain compliance. An extension of up to 180 days (through October 14, 2026) may be granted if the plan is accepted.

• Recent Capital Raises Acknowledged

  Vivos Therapeutics noted it raised $6.8 million in Q1 2026 through warrant exercises and a private placement, demonstrating its ability to raise funds, though these do not automatically cure the deficiency.

auto_awesomeAnalysis

This 8-K formalizes the Nasdaq non-compliance previously indicated in the company's recent 10-K. The company has negative stockholders' equity, falling significantly below Nasdaq's $2.5 million minimum. While Vivos has raised $6.8 million in Q1 2026, these funds do not automatically cure the deficiency, and the company must submit a plan to Nasdaq by June 1, 2026. Failure to regain compliance could result in delisting, which would severely impact the company's liquidity and investor confidence, especially for a micro-cap entity already facing a 'going concern' warning.